Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05029882 | Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab | active not recruiting | Phase 1 | 520 | AbbVieINDUSTRY | 10 | Oct 29, 2025 | clinicaltrials |
| NCT05205330 | Vorbipiprant (CR6086) / Balstilimab (AGEN2034) Combination in Stage IV Refractory pMMR - MSS CRC, and Other Metastatic GI Cancers | active not recruiting | Phase 1 / Phase 2 | 107 | Rottapharm BiotechINDUSTRY | 1 | Oct 29, 2025 |
| clinicaltrials |
| NCT04185883 | Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) | active not recruiting | Phase 1 | 610 | AmgenINDUSTRY | 13 | Oct 22, 2025 | clinicaltrials |
| NCT03889795 | Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors | active not recruiting | Phase 1 | 15 | Danae Hamouda, MDOTHER | 1 | Oct 20, 2025 | clinicaltrials |
| NCT05627063 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 169 | Abbisko Therapeutics Co, LtdINDUSTRY | 2 | Oct 20, 2025 | clinicaltrials |
| NCT04989556 | Technology-Enhanced Palliative Care for Advanced Cancer Patients | active not recruiting | N/A | 119 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT05642780 | SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors | active not recruiting | Phase 2 | 240 | Klus Pharma Inc.INDUSTRY | 6 | Oct 14, 2025 | clinicaltrials |
| NCT05948826 | First in Human Study of TORL-3-600 in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT06260774 | Study of TTX-MC138 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 16 | TransCode TherapeuticsINDUSTRY | 1 | Oct 2, 2025 | clinicaltrials |
| NCT03993873 | Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET(SHIELD-1) | active not recruiting | Phase 1 | 95 | Turning Point Therapeutics, Inc.INDUSTRY | 5 | Oct 1, 2025 | clinicaltrials |
| NCT04606472 | A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 60 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05385692 | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors | active not recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT03191682 | A First-in-Human Study of PRL3-ZUMAB | active not recruiting | Phase 1 | 38 | National University Hospital, SingaporeOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT05163028 | A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations | active not recruiting | Phase 1 | 42 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT05485974 | A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation | active not recruiting | Phase 1 | 44 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 24, 2025 | clinicaltrials |
| NCT05138991 | Reproducibility and Accuracy of a Portable System for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors | active not recruiting | N/A | 149 | City of Hope Medical CenterOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT05246670 | PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy | active not recruiting | Phase 2 | 88 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT04632108 | A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Patients With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 199 | Jiangsu Aosaikang Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 11, 2025 | clinicaltrials |
| NCT05653882 | A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | active not recruiting | Phase 1 | 552 | Asher Biotherapeutics, Inc.INDUSTRY | 1 | Sep 10, 2025 | clinicaltrials |
| NCT07151807 | Serum IGF-1 and IGF-1Ec in Malignancy Assessment(SIGMA) | active not recruiting | — | 100 | Çanakkale Onsekiz Mart UniversityOTHER | 1 | Sep 3, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT06036121 | A Study of ADRX-0706 in Select Advanced Solid Tumors | active not recruiting | Phase 1 | 144 | Adcentrx TherapeuticsINDUSTRY | 2 | Aug 17, 2025 | clinicaltrials |
| NCT07122063 | Clinical Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SYS6045 in Patients With HER2-Positive, Expressing, or Mutated Advanced Malignant Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 266 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 14, 2025 | clinicaltrials |
| NCT05717348 | A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours | active not recruiting | Phase 1 | 120 | Elpiscience (Suzhou) Biopharma, Ltd.INDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06547957 | A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors | active not recruiting | Phase 1 | 55 | iTeos TherapeuticsINDUSTRY | 1 | Aug 13, 2025 | clinicaltrials |
| NCT06480240 | A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 117 | OBI Pharma, IncINDUSTRY | 2 | Aug 8, 2025 | clinicaltrials |
| NCT05718557 | Study of PYX-106 in Solid Tumors | active not recruiting | Phase 1 | 47 | Pyxis Oncology, IncINDUSTRY | 3 | Aug 3, 2025 | clinicaltrials |
| NCT02304809 | Phase 2 Study Assessing Secured Access to Vemurafenib for Patients With Tumors Harboring BRAF Genomic Alterations(AcSé) | active not recruiting | Phase 2 | 216 | UNICANCEROTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06105021 | Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor | active not recruiting | Phase 1 / Phase 2 | 100 | Affini-T Therapeutics, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT05275777 | A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 66 | National University Hospital, SingaporeOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT06428500 | QTX3046 in Patients With KRAS G12D Mutations | active not recruiting | Phase 1 | 240 | Quanta TherapeuticsINDUSTRY | 1 | Jul 25, 2025 | clinicaltrials |
| NCT01843413 | Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases | active not recruiting | Phase 1 | 33 | Case Comprehensive Cancer CenterOTHER | 1 | Jul 20, 2025 | clinicaltrials |
| NCT06610227 | A Study of the RNA Tumor Vaccine Targeting MICA/B in Patients With Advanced Solid Tumors | active not recruiting | Early Phase 1 | 18 | NING LIOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT05354323 | NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors | active not recruiting | Phase 1 | 6 | NEC OncoImmunity ASINDUSTRY | 1 | Jun 26, 2025 | clinicaltrials |
| NCT04706676 | Integrative Neuromuscular Training in Adolescents and Children Treated for Cancer(INTERACT) | active not recruiting | N/A | 132 | Rigshospitalet, DenmarkOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04946968 | Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers | active not recruiting | Phase 2 | 24 | National Cancer Centre, SingaporeOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05888831 | A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 100 | Bristol-Myers SquibbINDUSTRY | 6 | Jun 11, 2025 | clinicaltrials |
| NCT02608385 | Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors | active not recruiting | Phase 1 | 117 | University of ChicagoOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04706715 | LAG3 PET Imaging in Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 41 | University Medical Center GroningenOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT05704985 | Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors | active not recruiting | Phase 1 | 39 | DEKA BiosciencesINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT05251714 | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Treadwell Therapeutics, IncINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT05167071 | HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | active not recruiting | Phase 1 | 53 | Harbour BioMed (Guangzhou) Co. Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT05919537 | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | active not recruiting | Phase 1 | 68 | Hummingbird BioscienceINDUSTRY | 1 | Apr 18, 2025 | clinicaltrials |
| NCT04706962 | TH1902 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 70 | TheratechnologiesINDUSTRY | 2 | Apr 15, 2025 | clinicaltrials |
| NCT04877717 | A Study of SHR-A1904 in Patients With Advanced Solid Cancer | active not recruiting | Phase 1 | 107 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Mar 25, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Oct 29, 2025source: clinicaltrials